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Abstract 
Background Cognitive impairment is strongly linked with persistent disability in people with 
mood disorders, but the factors that explain cognitive impairment in this population are 
unclear.  
Aims We aimed to estimate the total effect of (i) bipolar disorder (BD) and (ii) major 
depression on cognitive function, and the magnitude of the effect that was explained by 
potentially modifiable intermediate factors.  
Method Cross-sectional study using baseline data from the UK Biobank cohort. Participants 
were categorised as BD (N=2,709), major depression (N=50,975), or no mood disorder 
(N=102,931 to 105,284). The outcomes were computerised tests of reasoning, reaction time 
and memory. The potential mediators were cardiometabolic disease and psychotropic 
medication. Analyses were informed by graphical methods, and controlled for confounding 
using regression, propensity score-based methods, and G-computation.  
Results Group differences of small magnitude were found on a visuospatial memory test. Z-
score differences for BD were in the range -0.23 to -0.17 (95% CI range -0.39 to -0.03) 
across different estimation methods, and approximately -0.07 (95% CI -0.10 to -0.03) for 
major depression. One-quarter of the effect was mediated via psychotropic medication in the 
BD group (-0.05; 95% CI -0.09 to -0.01). No evidence was found for mediation via 
cardiometabolic disease.  
Conclusions In a large community-based sample in middle to early old age, BD and 
depression were associated with lower visuospatial memory performance, in part potentially 
due to psychotropic medication use. Mood disorders and their treatments will have increasing 
importance for population cognitive health as the proportion of older adults continues to 
grow. 
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Introduction 
Cognitive impairment is a key determinant of occupational and social outcomes and quality 
of life in people with mood disorders.1,2 Up to 57% of adults with bipolar disorder (BD) and 
up to one-half of adults with major depression show clinically significant levels of cognitive 
impairment, even in euthymia.3,4 In BD, impairment is typically found on tests of attention, 
working and episodic memory, processing speed, and executive function, with group 
differences of medium to large effect size compared with adults without a history of 
psychiatric illness.5,6 The profile of impairment is similar in major depression, but with effect 
sizes of smaller magnitude.7 The causal nature of this relationship is unclear, however, 
because approaches to accounting for confounding influences have been inconsistent in the 
literature. Moving towards causal explanations requires careful modelling of a range of 
potential confounding, mediating and moderating factors, acknowledging the complexity of 
their inter-relationships with mood disorder exposure, cognitive outcome, and each other. The 
application of novel confounder control techniques in psychiatric epidemiology is not yet 
widespread. The counterfactual approach, in which causal effects are conceptualized as 
alternative ‘potential outcomes’ of an exposure, can be linked with graphical notation in the 
form of directed acyclic graphs (DAG) to systematically identify causal effects in complex 
systems.8,9 This, in turn, informs rigorous statistical analyses and clarifies the assumptions 
needed to interpret estimates as causal. In this study, we applied a graphical approach to 
understand the structure of confounding and mediation with regard to cognitive performance 
in UK Biobank10 participants with a history of BD or major depression. We estimated the 
total effect of BD and major depression on cognitive function, and the magnitude of the effect 
that was transmitted through potentially modifiable intermediate factors. 
Method 
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Participants 
UK Biobank recruited adults from the general population across 22 centres in Great Britain 
between 2006 and 2010. The target age range was 40 to 69 years and no other exclusion 
criteria were applied. Postal invitation lists were generated from National Health Service 
(NHS) registers, with a response rate of approximately 6%. Cross-sectional data from the full 
cohort at baseline (N=502,618) were used. Participants were included in the analysis if they 
had sufficient data to classify their BD or major depression exposure status (see below) and 
had data on at least one cognitive outcome measure. The authors assert that all procedures 
contributing to this work comply with the ethical standards of the relevant national and 
institutional committees on human experimentation and with the Helsinki Declaration of 
1975, as revised in 2008. All procedures involving human participants were approved by the 
North West - Haydock NHS Research Ethics Committee (reference 16/NW/0274 and 
11/NW/0382). Written informed consent was obtained from all participants. 
Mood Disorder Status 
Three sources of information were available regarding history of mood disorder: self-reported 
doctor diagnosis; probable classification based on self-reported lifetime mood disorder 
symptoms and help-seeking;11 and linked NHS hospital inpatient and day case records. The 
definitions used in these sources are provided in the eMethods in the Supplement. To permit 
consistency across each information source, single manic episode and BD were analysed as 
one exposure (mania/BD), and the major depression exposure included single episode and 
recurrent illness.  
Participants were classified as exposed if they were positive for mania/BD or major 
depression in at least one information source. Mania/BD and major depression were then 
separated hierarchically into two mutually exclusive exposure groups. Participants with a 
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record of both mania/BD and major depression were classified in the mania/BD group only. 
The unexposed comparison group comprised participants who had complete self-reported 
data that did not indicate mania/BD or major depression, and whose hospital records had no 
primary or secondary diagnosis of mania/BD or major depression. Furthermore, because 
misclassification is common between mania/BD and schizophrenia spectrum disorders,12 
participants with a self-reported diagnosis or hospital record of schizophrenia (ICD-10 code 
F20x) were excluded from all exposed and unexposed groups. In summary, the final groups 
for analysis were: mania/BD (excluding participants with only major depression, and those 
with schizophrenia); major depression (excluding participants with mania/BD, and those with 
schizophrenia); and unexposed (complete data indicating no mania/BD or major depression 
or schizophrenia). Participants who did not meet the above criteria for either the exposed or 
unexposed groups were not further analysed (e.g. those with incomplete data, preventing 
inclusion in the unexposed group).  
Cognitive Outcome Measures 
The cognitive measures analysed were reasoning, reaction time, numeric memory, 
visuospatial memory and prospective memory, as described in detail elsewhere.13 All were 
administered via a touchscreen computer. The psychometric properties of these tests have 
been reported previously.14 The data were provided by UK Biobank as raw scores, and for the 
purposes of the present analysis were standardized within five-year age strata, using all 
available data in the cohort at baseline. Five-year bands were deemed appropriate in light of 
the typical rate of age-related change in cognitive performance in middle to older 
adulthood.15 To address skew in the raw data distributions, the scores were first transformed 
into percentiles and then into z-scores (mean = 0 and standard deviation [SD] = 1). The 
scores for reaction time and visuospatial memory were reflected so that higher scores 
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represent better performance, in line with the other tests. It was not possible to standardize 
the prospective memory data in this way because responses were dichotomized (correct 
response at the first attempt or not), and so the raw data were used in the analyses involving 
this test.  
Covariates  
Sociodemographic, environmental, lifestyle and physical measures 
Details of these measures are provided in the eMethods in the Supplement. Briefly, the 
sociodemographic variables were age, gender, ethnic background, country of birth, 
educational attainment, and neighbourhood deprivation level. Local environment measures 
comprised population density, proximity to the nearest major road, and air pollutants 
(particulate matter and nitrogen dioxide). Lifestyle and physical measures comprised 
smoking, alcohol consumption, insomnia, physical activity, and body mass index (BMI). 
Medical and family history  
A dichotomous indicator was created for history of any cardiometabolic disease (self-
reported diagnosis of angina, hypertension or non-gestational diabetes, or adjudicated 
diagnosis of myocardial infarction or stroke; see eMethods in the Supplement). A 
dichotomous indicator was also created for history of any neurological or psychiatric 
condition (apart from mood disorder or schizophrenia) in the self-reported or hospital records 
data; the conditions included are listed in the eMethods in the Supplement. Family history of 
certain illnesses in biological parents and siblings was included in the baseline questionnaire, 
and for the present analyses dichotomous indicators were generated for history of psychiatric 
or neurological conditions (dementia, Parkinson’s disease, or severe depression, coded 
separately) in any parent or sibling. Participants also self-reported whether their mothers had 
smoked regularly around the time of their birth.  
  
7 
 
Mental health and psychotropic medication 
In addition to the self-reported and hospital records data regarding psychiatric diagnoses, 
participants also provided self-reported information at baseline about depressive symptoms in 
the past two weeks, and current psychotropic medications (dichotomous indicator for any 
mood stabilizer, antidepressant, antipsychotic, sedative or hypnotic), as detailed in the 
eMethods in the Supplement. Self-reported information regarding number of episodes of 
depressed mood or anhedonia was collected at baseline and in a web-based follow-up 
questionnaire in 2016, and data regarding childhood trauma experiences were also collected 
in the web-based questionnaire (see eMethods). 
Genome-wide polygenic scores 
Genome-wide polygenic scores (GPS) were generated for cognitive ability, BD, and major 
depression, based on summary statistics from previous genome-wide association studies 
(GWAS). Full details of the genotyping data, GPS methods, and optimum scores used in the 
present analyses are provided in the eMethods in the Supplement.  
Statistical Analyses 
Graphical models 
The analyses were informed by a graphical model in the form of a DAG, which is used to 
visually represent qualitative causal assumptions.16 The structural nature of these assumptions 
permits the detection of implied patterns of dependency and independency among variables, 
which can then be tested with data. Structural analysis of the DAG allows confounders, 
mediators and colliders to be distinguished when planning multivariable analyses.16  
A DAG was constructed to represent plausible causal assumptions about the relationship 
between lifetime history of mania/BD and cognitive performance, in the context of possible 
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confounding factors and intermediate pathways. This was done before any data were 
analysed. The nodes in the DAG and the assumed directional relationships between them 
were determined from previous systematic reviews of cognitive function in BD,3,5,17-24 as well 
as general background knowledge and assumptions regarding other shared causes that were 
necessary to depict in order for the DAG to have a causal interpretation.16 The fit of the DAG 
to the data was then evaluated by estimating partial correlation coefficients for each pair of 
nodes that were predicted to be independent. Detection of a correlation between nodes that 
were predicted to be independent may indicate that the DAG has been misspecified. Where 
the results indicated lack of independence (i.e. partial correlation coefficient >|0.1|25), follow-
up regression models were conducted to obtain further detail. Modifications to the structure 
of the DAG were then considered. A detailed account of the construction and evaluation of 
the DAG is provided in the eMethods in the Supplement.  
The DAG used in the major depression analyses was based on the final DAG used in the 
mania/BD analyses, with an arrow added from gender to major depression; studies have 
consistently shown higher prevalence of depression in women,26 and it was assumed in the 
DAG that this relationship was at least partly causal. No arrows were removed compared 
with the mania/BD DAG, on the assumption that similar causal relationships might be 
operating to explain cognitive impairment in both disorders. 
Total effects 
The total effect of each mood disorder exposure on cognitive performance was firstly 
identified in the DAGs using DAGitty software.27 The DAGitty algorithm applies ‘d-
separation’ rules8,28 to find all the confounding paths between the exposure and the outcome, 
and ascertains if there is a set of nodes which, if conditioned on in the analysis, would ‘block’ 
these confounding paths. This information was then used to plan regression- and matching-
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based analyses to estimate the effect in the dataset. This was estimated separately for each of 
the five cognitive outcome measures, to allow for the possibility of task-specific variation in 
the results. Results are reported as standardized mean differences or risk differences with 
95% confidence intervals (CI). Further details of the estimation methods are given in the 
eMethods in the Supplement.  
Mediation analyses 
The DAGs were used to assess whether indirect effects via various mediators of interest 
could be identified. This required all confounding paths between the exposure and the 
mediator and between the mediator and the outcome to be blocked, as well as those between 
the exposure and the outcome. Where this requirement was satisfied (i.e. covariate 
adjustment sets could be found), G-computation was used to estimate the natural direct and 
indirect effects.29 This was implemented using the Stata package gformula;30 gformula 
permits mediation analysis in the presence of intermediate confounding, whereby a mediator-
outcome confounder is itself caused by the exposure. Results are reported as standardized 
mean differences or risk differences with 95% CI. 
Sensitivity analyses 
Additional analyses were conducted to evaluate the sensitivity of the results to various 
potential sources of bias, including residual confounding, missing data, and exposure 
misclassification (see eMethods in the Supplement). These informed our interpretation with 
regard to key threats to the validity of the analytic framework. 
Reporting follows STROBE guidelines.31 
Results 
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Cognitive Impairment in Mania/BD 
Characteristics of the sample 
eFig. 2 in the Supplement shows a flowchart of exclusions leading to the final analysis 
sample, which comprised 2,709 participants with mania/BD and 105,284 comparison 
participants. The descriptive results indicated worse cognitive performance and less 
favourable covariate characteristics in the mania/BD group, although they were younger on 
average and more likely to have a degree (Table 1 and eTable 5). 
[Table 1 about here] 
Evaluation of the graphical model 
The original DAG is shown and explained in the eMethods in the Supplement. The different 
predicted independencies implied by alternative plausible specifications of this DAG were 
tested (see eResults in the Supplement for details). eFig. 3 in the Supplement shows the best 
fitting DAG, which was used as the basis for the analysis models.  
Total effects 
Only the visuospatial memory test (Fig. 1) and, more equivocally, the prospective memory 
test (eFig. 4 in the Supplement) indicated a detrimental effect of mania/BD that remained 
evident in the multivariable models. The effect sizes were small: the mania/BD group scored 
approximately 0.2 SD lower than the unexposed comparison group on the visuospatial 
memory test, and the proportion of the mania/BD group succeeding on the prospective 
memory task was lower by approximately 5 percentage points (approximately 82% in the 
mania/BD group versus 87% in the unexposed group). The visuospatial and prospective 
memory estimates showed little change between the unadjusted and adjusted/matched 
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models, whereas the estimates for the other three cognitive measures generally attenuated 
towards the null (see eFigs. 5 to 7 in the Supplement).  
[Fig. 1 about here] 
Mediation analyses 
Structural analysis of the DAG indicated that direct and indirect effects could be decomposed 
for two potentially modifiable mediators: cardiometabolic disease and psychotropic 
medication. Further details of these models are provided in the eResults in the Supplement.  
There was no evidence of substantive indirect effects via cardiometabolic disease in any of 
the models (eTable 8 in the Supplement).  
There was evidence that the previously-noted detrimental effect of mania/BD on visuospatial 
memory was indirectly transmitted via psychotropic medication (eTable 9 in the 
Supplement). Of the estimated total effect of -0.19 SD units (95% CI -0.31 to -0.08), 
approximately one quarter was mediated via psychotropic medication (-0.05; 95% CI -0.09 to 
-0.01). Indirect effects were also evident in the reasoning, reaction time and prospective 
memory models, although the total effects estimates in these models did not show reliable 
decrements for mania/BD.  
Sensitivity analyses 
The results of the sensitivity analyses are provided in the eResults in the Supplement. Briefly, 
these indicated that: the total effects results for visuospatial memory are likely to be sensitive 
to exposure misclassification and would not be robust to an unmeasured confounder with 
even a weak association with exposure group membership (leading to minimally unbalanced 
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odds of exposure, i.e. 45/55); the total effects results showed less attenuation when missing 
covariate data were imputed; the mediation results with missing covariate data imputation 
showed stronger evidence for an indirect effect via psychotropic medication but no evidence 
of an indirect effect via cardiometabolic disease; the DAGitty algorithm determined that there 
were six other DAGs that were equivalent to the DAG shown in eFig. 3 in the Supplement, 
but none of these alternative configurations was causally plausible. 
Cognitive Impairment in Major Depression 
Characteristics of the sample 
eFig. 9 in the Supplement shows that the analysis sample comprised 50,975 participants with 
major depression and 102,931 comparison participants. Table 2 summarizes their cognitive 
outcome data, and eTable 12 in the Supplement summarizes their covariate data. 
[Table 2 about here] 
Evaluation of the graphical model 
The different predicted independencies implied by alternative plausible specifications of the 
DAG were tested (see eResults in the Supplement). The best fitting DAG followed the same 
structure as that used in the mania/BD analysis, with the addition of a path between gender 
and major depression.  
Total effects 
Major depression was negatively associated with visuospatial memory performance in the 
multivariable models (Fig. 2). The effect size was very small, with the major depression 
group scoring approximately 0.07 SD lower than the comparison group. Group differences 
were not seen on the other cognitive measures (eFigs. 10 to 13 in the Supplement).  
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[Fig. 2 about here] 
Mediation analyses 
As with the mania/BD analyses, direct and indirect effects could be decomposed via 
cardiometabolic disease and via psychotropic medication (see eResults in the Supplement). 
There was no evidence of substantive indirect effects via cardiometabolic disease in any of 
the models (eTable 16 in the Supplement). There was little evidence of mediation via 
psychotropic medication (eTable 17): approximately one third of the total effect on 
visuospatial memory (itself of very small magnitude, at -0.058) was estimated to be indirect, 
but the confidence interval included the null (-0.019; 95% CI -0.040 to 0.003). 
Sensitivity analyses 
The sensitivity analyses (eResults in the Supplement) indicated that: the total effects results 
for visuospatial memory are likely to be sensitive to exposure misclassification and would not 
be robust to an unmeasured confounder with even a very weak association with exposure 
group membership; the total effects results for reaction time showed less attenuation when 
missing covariate data were imputed; the mediation results with missing covariate data 
imputation showed stronger evidence for an indirect effect via psychotropic medication but 
no evidence of an indirect effect via cardiometabolic disease; there were six structurally 
equivalent DAGs but none were causally plausible. 
Discussion 
This study demonstrates small but robust associations between mood disorders and cognitive 
function in a large community-based sample, with rigorous confounder control based on 
extensively evaluated graphical models and analytical methods. A total effect of mania/BD 
on cognitive function was evident on a test of short-term visuospatial memory, but not on 
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other tests. The magnitude of this effect was small, with the point estimates across the various 
matched/adjusted models being in the range -0.23 to -0.17 standard deviation units. There 
was evidence of an indirect pathway through psychotropic medication, accounting for 
approximately one-quarter of the total effect, but (perhaps surprisingly) not through 
cardiometabolic disease. The total effect of major depression on cognitive performance 
followed a similar pattern to that of mania/BD, though with an effect size of around one-third 
the magnitude. The proportion of the total effect mediated by psychotropic medication was 
similar to that in mania/BD, but the confidence interval was wide and the estimate was 
reliably different from the null only after imputation of missing data. The effect estimates for 
both mood disorders are likely to be sensitive to residual confounding and exposure 
misclassification, and they may be biased toward the null as a result of missing covariate 
data.  
The complexity inherent in this area was acknowledged and addressed by developing and 
evaluating comprehensive graphical models and by incorporating a broad range of genetic, 
sociodemographic, environmental, lifestyle and clinical measures in the analyses. Model 
estimation was conducted in multiple ways, and quantitative and graphical sensitivity 
analyses were carried out to investigate the robustness of the results to key assumptions. The 
sample sizes were substantially larger than those used in previous studies in the field, 
allowing small effect sizes to be estimated with precision.  
The observed gradation in severity of impairment on the visuospatial memory task across 
mania/BD and major depression is congruent with previous reports,7 although the magnitude 
of the difference compared with the non-mood-disorder group is notably smaller.17-19,22 The 
absence of group differences on the other cognitive tasks was surprising, in light of previous 
research showing multi-domain impairments, and it remains unclear to what extent this 
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reflects insufficient adjustment for confounding in previous studies, the characteristics of the 
UK Biobank cohort, or the possibility that memory performance is a particularly sensitive 
marker of cognitive function in mood disorders.  
The results also contribute to the evidence base on the relationship between psychotropic 
medication and cognitive impairment, which has been repeatedly highlighted in previous 
studies.32 Mediation analyses, taking account of intermediate confounders such as past 
depressive episodes, indicated that an appreciable proportion of the detrimental effect of 
mania/BD on visuospatial memory performance was accounted for by this. The interplay 
between reasons for prescribing—especially of antipsychotic medications—and affective 
remission in understanding this relationship is not yet understood, but the present results 
appear to confirm that psychotropic medications warrant closer study as potential modifiable 
causes of cognitive impairment in mood disorders.  
Limitations 
The analyses were necessarily limited by the data collected in the UK Biobank resource: 
many of the measures were brief, key cognitive functions such as verbal memory were not 
assessed, and clinician diagnoses were unavailable. The reliability of some of the cognitive 
measures is suboptimal.14 This may cause imprecision in effect size estimates,33 but such 
imprecision is mitigated by the large sample size in the present study. However, imprecision 
that is not due to random error could result in underestimated magnitudes of associations. The 
cognitive tests administered in UK Biobank may be less sensitive than the 
neuropsychological assessments used in clinical studies, which may partly account for the 
small group differences observed here. Assumptions about the temporal order of the variables 
could not be verified empirically. Conducting estimation one mediator at a time may lead to 
erroneous conclusions about the contribution of each mediator to the overall effect.34 Possible 
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collider stratification bias should be acknowledged;35 it is likely that people with less severe 
mood disorder history and better cognitive function will have joined UK Biobank, and this 
will have been amplified further in the patterns of missingness across the cognitive outcome 
measures and the covariates. What is unknown, however, is the magnitude of the bias arising 
from collider stratification, and how this compares with similar or opposing biases from 
residual confounding. The missing-at-random assumption that is required for multiple 
imputation is arguably not valid for some of the measures in these analyses, given the 
probability that, for example, missingness on mental health-related measures will be 
influenced by true mental health status. Finally, the UK Biobank cohort is not representative 
of the UK population; associations may be heterogeneous across other populations.36 
Conclusions and Future Directions 
A small group difference in visuospatial memory performance was observed between mood 
disorder and comparison groups in this large general population cohort. Mediation analyses 
highlighted a potential causal pathway through psychotropic medication use. Our 
understanding of causal pathways towards cognitive impairment in psychiatric and 
neurological conditions will improve as the UK Biobank cohort is followed up over time, and 
other prospective cohorts such as the Avon Longitudinal Study of Parents and Children37 
mature into adulthood. The availability of a fuller range of background and intermediate data, 
including early life factors, premorbid cognitive ability measures and brain imaging, will 
expand the kinds of causal effects that can be identified in models such as those proposed 
here. Linkage with prescribing data will permit more detailed investigation of the role of 
different classes of psychotropic medication, and combinations thereof, in explaining adverse 
cognitive outcomes.   
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Table 1 Summary of Cognitive Outcome Measures in the Mania/Bipolar Disorder and 
Comparison Groups 
 All available data Complete covariate dataa 
 Mania/BD Comparison Mania/BD Comparison 
N  2,709 105,284 504 26,997 
Reasoning z-score 
N (%) missingb 
Mean (SD) 
Cronbach’s α 
 
31 (1.8) 
-0.35 (1.01) 
0.71 
 
1,627 (1.6) 
-0.20 (0.97) 
0.70 
 
1 (0.3) 
0.05 (0.96) 
0.70 
 
89 (0.3) 
0.12 (0.92) 
0.68 
Reaction time z-score  
N (%) missing 
Mean (SD)  
Cronbach’s α 
 
51 (1.9) 
-0.19 (1.01) 
0.82 
 
1,167 (1.1) 
-0.03 (0.98) 
0.82 
 
1 (0.2) 
0.03 (0.94) 
0.72 
 
72 (0.3) 
0.07 (0.96) 
0.82 
Numeric memory z-score 
N (%) missingb 
Mean (SD) 
 
18 (3.9) 
-0.52 (1.00) 
 
755 (2.4) 
-0.35 (0.94) 
 
0 (0.0) 
-0.23 (1.08) 
 
51 (0.7) 
-0.16 (0.93) 
Visuospatial memory z-score 
N (%) missing 
Mean (SD) 
 
157 (5.8) 
0.07 (1.07) 
 
2,896 (2.8) 
0.26 (1.05) 
 
10 (1.2) 
0.20 (1.09) 
 
212 (0.8) 
0.37 (1.03) 
Prospective memoryb,c 
N (%) correct 
 
1,264 (72.1) 
 
80,502 (76.9) 
 
286 (80.3) 
 
23,112 (85.7) 
BD, bipolar disorder; GPS, genome-wide polygenic score; SD, standard deviation. 
a. Participants with complete data on all the covariates that were entered into the maximally-adjusted total 
effects models (age, gender, white British genetic ancestry, English-speaking country of birth, degree, comorbid 
neurological/psychiatric condition, family history of dementia, family history of Parkinson’s disease, family 
history of severe depression, maternal smoking around birth, childhood trauma, education/cognition GPS, 
bipolar disorder GPS). 
b. Missing data refers only to the period when this measure was included in the battery. 
c. No missing data. 
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Table 2 Summary of Cognitive Outcome Measures in the Major Depression and Comparison 
Groups 
 All available data Complete covariate dataa 
 Major 
depression 
Comparison Major 
depression 
Comparison 
N 50,975 102,931 11,662 26,392 
Reasoning z-score 
N (%) missingb 
Mean (SD) 
Cronbach’s α 
 
421 (1.3) 
-0.20 (0.96) 
0.69 
 
1,584 (1.6) 
-0.20 (0.97) 
0.70 
 
25 (0.3) 
0.10 (0.90) 
0.66 
 
84 (0.3) 
0.13 (0.92) 
0.68 
Reaction time z-score  
N (%) missing 
Mean (SD)  
Cronbach’s α 
 
534 (1.1) 
-0.08 (0.98) 
0.82 
 
1,139 (1.1) 
-0.03 (0.98) 
0.82 
 
34 (0.3) 
0.04 (0.94) 
0.82 
 
68 (0.3) 
0.07 (0.95) 
0.82 
Numeric memory z-score 
N (%) missingb 
Mean (SD) 
 
252 (2.6) 
-0.39 (0.93) 
 
733 (2.4) 
-0.35 (0.94) 
 
18 (0.8) 
-0.24 (0.90) 
 
49 (0.7) 
-0.17 (0.93) 
Visuospatial memory z-score 
N (%) missing 
Mean (SD) 
 
1,653 (3.2) 
0.19 (1.05) 
 
2,843 (2.8) 
0.26 (1.05) 
 
106 (0.9) 
0.30 (1.04) 
 
206 (0.8) 
0.37 (1.03) 
Prospective memoryb,c 
N (%) correct 
 
25,006 (78.0) 
 
78,673 (76.8) 
 
7,003 (85.6) 
 
22,591 (85.7) 
GPS, genome-wide polygenic score; SD, standard deviation. 
a. Participants with complete data on all the covariates that were entered into the maximally-adjusted total 
effects models (age, gender, white British genetic ancestry, English-speaking country of birth, degree, comorbid 
neurological/psychiatric condition, family history of dementia, family history of Parkinson’s disease, family 
history of severe depression, maternal smoking around birth, childhood trauma, education/cognition GPS, major 
depression GPS). 
b. Missing data refers only to the period when this measure was included in the battery. 
c. No missing data. 
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Fig. 1 Total Effect of Mania/Bipolar Disorder on Visuospatial Memory. 
CI, confidence interval; GPS, genome-wide polygenic score; IPW, inverse probability 
weighting; IPWRA, inverse probability weighting with regression adjustment; teffects, Stata 
teffects package. Estimates are in z-score units and can be interpreted as standardized 
mean differences. The minimum sufficient adjustment set comprised gender, educational 
attainment, English-speaking birth country, ethnicity, education/cognition GPS, bipolar 
disorder GPS, family history of dementia or Parkinson’s disease, maternal smoking around 
birth, childhood trauma, and comorbid psychiatric/neurological conditions. The extended 
adjustment set (‘all common ancestors’) also included age and family history of depression. 
This extended adjustment set was used as the predictor set for the propensity score model. 
Ethnicity was accounted for in all the multivariable analyses and in the propensity score 
estimation by restricting these to participants of white British genetic ancestry. The GPS 
scores were residualized as described in the eMethods, and were entered as deciles, based on 
the distribution in the full analysis sample.  
 
Fig. 2 Total Effect of Major Depression on Visuospatial Memory. 
CI, confidence interval; GPS, genome-wide polygenic score; IPW, inverse probability 
weighting; IPWRA, inverse probability weighting with regression adjustment; teffects, Stata 
teffects package. Estimates are in z-score units and can be interpreted as standardized 
mean differences. The minimum sufficient adjustment set comprised gender, educational 
attainment, English-speaking birth country, ethnicity, education/cognition GPS, major 
depression GPS, family history of dementia or Parkinson’s disease, maternal smoking around 
birth, childhood trauma, and comorbid psychiatric/neurological conditions. The extended 
adjustment set (‘all common ancestors’) also included age and family history of depression. 
This extended adjustment set was used as the predictor set for the propensity score model. 
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Ethnicity was accounted for in all the multivariable analyses and in the propensity score 
estimation by restricting these to participants of white British genetic ancestry. The GPS 
scores were residualized as described in the eMethods, and were entered as deciles, based on 
the distribution in the full analysis sample. 
 


